“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.